$35.03+0.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Company outlook: revenue of $295M to $301M for Fiscal Q4 2026 — down 5.1% on a year earlier ($314M)
Just reported
From Omnicell, Inc.'s results release of October 29, 2026; its quarterly report has since been filed.
Actual
$307.9M
-0.9% y/y
-1.4% q/q
Guided
$304M
midpoint
Actual
$0.24
+100% y/y
-54% q/q
Guided
—
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $307.9M | $310.6M | -0.89% |
| Profit | $11M | $5.5M | +102.20% |
| Profit per share | $0.24 | $0.12 | +100.00% |
| Free Cash Flow | $21.7M | $18.5M | +17.15% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Omnicell, Inc. has no earnings call transcript available.
“We delivered solid third quarter results and continued to execute against our strategic priorities,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Omnicell is a healthcare technology leader focused on advancing autonomous medication management to drive meaningful outcomes across the patient care journey. Through AI-enabled innovation, enterprise intelligence, and scalable automation, we seek to connect and optimize medication management from orders to outcomes, empowering healthcare organizations worldwide to improve efficiency, enhance safety, strengthen financial performance, and deliver better experiences for patients and care teams. Learn more at omnicell.com. From time to time, Omnicell may use the Company’s investor relations website and other online social media channels, including its LinkedIn page www.linkedin.com/company/omnicell, and Facebook page www.facebook.com/omnicellinc, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (“Reg FD”). OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries. This press release may also include the trademarks and service marks of other companies. Such trademarks and service marks are the marks of their respective owners.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Omnicell, Inc.’s Item 2.02 8-K filed October 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
No guide given
Actual
$14.9M
+81% y/y
-54% q/q
Guided
—
No guide given
Q4 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.